Sanifit Therapeutics S. A.
Quick facts
Phase 3 pipeline
- Experimental: SNF472 · Nephrology / Cardiovascular
SNF472 is a calcimimetic agent that binds to and activates the calcium-sensing receptor to reduce serum phosphate levels in patients with chronic kidney disease.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Sanifit Therapeutics S. A.
What is Sanifit Therapeutics S. A.'s pipeline?
Sanifit Therapeutics S. A. has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Experimental: SNF472.
Related
- Sector hub: All tracked pharma companies